Misclassified Alcohol-related Liver Disease is Common in Presumed Metabolic Dysfunction-associated Steatotic Liver Disease and Highly Increases Risk for Future Cirrhosis

被引:20
作者
Nasr, Patrik [1 ,2 ]
Wester, Axel [2 ]
Ekstedt, Mattias [1 ]
Strandberg, Rickard [2 ]
Kechagias, Stergios [1 ]
Shang, Ying [2 ]
Widman, Linnea [2 ]
Hagstrom, Hannes [2 ,3 ]
机构
[1] Linkoping Univ, Dept Hlth Med & Caring Sci, Div Diagnost & Specialist Med, Linkoping, Sweden
[2] Karolinska Inst, Dept Med, C1 77, S-14186 Stockholm, Sweden
[3] Karolinska Univ Hosp, Dept Upper GI, Div Hepatol, Stockholm, Sweden
关键词
Alcohol-related Liver Disease; Alcohol Use Disorder; Epidemiology; MAFLD; MetALD; NAFLD; CONSUMPTION; PHOSPHATIDYLETHANOL; BLOOD; PETH; FIBROSIS; MARKER;
D O I
10.1016/j.cgh.2024.01.006
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BACKGROUND & AIMS: Alcohol overconsumption is a risk factor for disease progression in patients with presumed metabolic dysfunction-associated steatotic liver disease (MASLD). How commonly this occurs and how it affects progression to major adverse liver outcomes (MALOs) is not well known. METHODS: We did a register-based cohort study, including all patients with a diagnosis of MASLD in Sweden between 1987 and 2020. Patients were strati fi ed on co-occurrence of diagnoses of alcohol-related liver disease (ALD) or alcohol use disorder (AUD) prior to MASLD diagnosis. Incident MALOs were derived from national registers. Cox regression was used to calculate hazard ratios (HRs) for incident MALO. RESULTS: A total of 15,107 patients with MASLD were identi fi ed. The median age was 55 years, and 52% were female. Of the patients, 1843 (12%) had a prior diagnosis of ALD or AUD. During followup, a further 787 patients (5.2%) received a diagnosis of ALD or AUD. Patients with previous ALD or AUD diagnoses at or before baseline had considerably higher rates of MALOs compared with patients without (19.5% vs 7.8%; adjusted HR, 3.12; 95% con fi dence interval, 2.74 - 3.55). Acquiring an ALD or AUD diagnosis after MASLD diagnosis was associated with higher rates of MALOs (adjusted HR, 5.81; 95% con fi dence interval, 4.90 - 6.88). CONCLUSIONS: ALD or AUD is commonly diagnosed prior to or after MASLD diagnosis. Such patients have considerably higher rates of progression to MALOs. Correctly separating between MASLD and ALD is vital to assess prognosis.
引用
收藏
页码:1048 / 1057.e2
页数:12
相关论文
共 50 条
  • [41] Evolutionary aspects of metabolic dysfunction-associated steatotic liver disease (MASLD)
    Geier, Andreas
    Schiffels, Stephan
    Krawczyk, Marcin
    GASTROENTEROLOGIE, 2025, : 94 - 103
  • [42] Lymph Node Adiposity and Metabolic Dysfunction-Associated Steatotic Liver Disease
    Rubino, Jessica M.
    Ring, Natalie Yanzi
    Patel, Krishna
    Xia, Xiaoqing
    Mackenzie, Todd A.
    diFlorio-Alexander, Roberta M.
    BIOMEDICINES, 2025, 13 (01)
  • [43] Role of the Gut Microbiome in Metabolic Dysfunction-Associated Steatotic Liver Disease
    Maher, Salim
    Rajapakse, Jayashi
    El-Omar, Emad
    Zekry, Amany
    SEMINARS IN LIVER DISEASE, 2024, 44 (04) : 457 - 473
  • [44] Endoscopic sleeve gastroplasty for metabolic dysfunction-associated steatotic liver disease
    Matteo, Maria Valeria
    Gualtieri, Loredana
    Bove, Vincenzo
    Palumbo, Giulia
    Pontecorvi, Valerio
    De Siena, Martina
    Barbaro, Federico
    Spada, Cristiano
    Boskoski, Ivo
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2024, 18 (08) : 397 - 405
  • [45] Liver tissue lipids in metabolic dysfunction-associated steatotic liver disease with diabetes and obesity
    Sourianarayanane, Achuthan
    Brydges, Christopher R.
    McCullough, Arthur J.
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2024, 48 (07)
  • [46] Iron, Oxidative Stress, and Metabolic Dysfunction-Associated Steatotic Liver Disease
    Gensluckner, Sophie
    Wernly, Bernhard
    Datz, Christian
    Aigner, Elmar
    ANTIOXIDANTS, 2024, 13 (02)
  • [47] Metabolic dysfunction-associated steatotic liver disease and its link to cancer
    Kalligeros, Markos
    Henry, Linda
    Younossi, Zobair M.
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2024, 160
  • [48] New Nomenclature for Nonalcoholic Fatty Liver Disease: Understanding Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction- and Alcohol-Associated Liver Disease, and Their Implications in Clinical Practice
    Canivet, Clemence M.
    Boursier, Jerome
    Loomba, Rohit
    SEMINARS IN LIVER DISEASE, 2024, 44 (01) : 35 - 42
  • [49] The prevalence and predictors of metabolic dysfunction-associated steatotic liver disease and fibrosis/cirrhosis among adolescents/young adults
    Perumpail, Brandon J.
    Manikat, Richie
    Wijarnpreecha, Karn
    Cholankeril, George
    Ahmed, Aijaz
    Kim, Donghee
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2024, 79 (01) : 110 - 118
  • [50] Prevalence and Clinical Correlation of Cardiometabolic Risk Factors in Alcohol-Related Liver Disease and Metabolic Dysfunction and Alcohol Associated Liver Disease (MetALD)
    Dixon, Wesley
    Corey, Kathleen E.
    Luther, Jay
    Goodman, Russell P.
    Schaefer, Esperance A.
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2025, 15 (03)